+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rheumatoid Arthritis Diagnosis Tests Market by Test Type, Technology, End User, Sample Type - Global Forecast to 2030- Product Image
Rheumatoid Arthritis Diagnosis Tests Market by Test Type, Technology, End User, Sample Type - Global Forecast to 2030- Product Image
Sale

Rheumatoid Arthritis Diagnosis Tests Market by Test Type, Technology, End User, Sample Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012404
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Rheumatoid Arthritis Diagnosis Tests Market grew from USD 3.08 billion in 2024 to USD 3.23 billion in 2025. It is expected to continue growing at a CAGR of 4.91%, reaching USD 4.11 billion by 2030.

Setting the Stage for Diagnostic Innovation

Rheumatoid arthritis remains a pervasive chronic autoimmune condition that affects millions worldwide, and accurate, timely diagnosis is critical for optimizing patient outcomes. In recent years, advances in both serological markers and imaging modalities have transformed the diagnostic pathway. Immunoassays targeting anti-cyclic citrullinated peptide and rheumatoid factor have achieved greater sensitivity and specificity, while high-resolution ultrasound and MRI techniques enable earlier detection of joint inflammation and erosions.

This executive summary synthesizes the complex interplay of technological innovation, regulatory shifts, and market dynamics shaping rheumatoid arthritis diagnostic testing. By presenting key developments, regional nuances, and actionable recommendations, it delivers a clear roadmap for stakeholders seeking to capitalize on emerging opportunities and address ongoing challenges. Throughout this report, we balance rigorous analysis with accessible explanations to equip decision-makers with the insights required to navigate a rapidly evolving landscape.

Evolving Paradigms Shaping Diagnostic Practice

The diagnostic landscape for rheumatoid arthritis has undergone transformative shifts driven by both technology and patient-centric care models. The rise of point-of-care testing has empowered clinicians to deliver rapid serological results in outpatient settings, reducing time to diagnosis and enabling prompt treatment initiation. Simultaneously, the integration of artificial intelligence into imaging platforms has enhanced lesion detection and quantification, elevating the objectivity of ultrasound and MRI assessments.

Moreover, the convergence of multiplex immunoassay panels and digital health apps is fostering a more holistic approach to disease monitoring. Patients can now receive continuous feedback on inflammatory markers through smartphone-connected devices, facilitating tighter disease control and personalized therapy adjustments. These trends underscore a broader shift toward decentralized, data-driven diagnostic models that prioritize both clinical precision and patient experience.

Assessing Tariff Impacts on Diagnostic Supply Chains

The implementation of new tariff measures in the United States for 2025 is poised to influence the cost structure and supply chain of diagnostic reagents and instrumentation. Increased duties on imported assay kits and imaging components have the potential to elevate prices for end users, while prompting domestic manufacturers to scale up production capacity. In response, several stakeholders have begun diversifying their supplier base to mitigate exposure to geopolitical risks.

These adjustments may inevitably lead to a recalibration of pricing strategies and reimbursement frameworks, as payers and healthcare providers seek to balance cost containment with the imperative of maintaining diagnostic quality. Despite potential short-term disruptions, the long-term effect of tariffs could catalyze innovation in local manufacturing and foster greater supply chain resilience, ultimately benefiting patient access to advanced diagnostic modalities.

Unpacking Segmentation-Driven Market Dynamics

Examining market segmentation through the lens of test type, technology, end user, and sample type reveals nuanced growth drivers and competitive differentiators. Within test type classifications, anticcp assays span first-, second-, and third-generation cyclic citrullinated peptide tests, each iteration offering incremental gains in diagnostic accuracy. C reactive protein tests range from conventional assays to high-sensitivity platforms that detect subclinical inflammation, while erythrocyte sedimentation rate testing is available in both automated and manual formats. Imaging tests encompass CT, MRI, ultrasound, and X-ray, allowing clinicians to tailor diagnostic strategies according to disease stage and resource availability. Rheumatoid factor testing includes IgA, IgG, and IgM isotypes, providing complementary insights into autoantibody profiles.

In parallel, the technology dimension spans chemiluminescent immunoassays-both direct and indirect CLIA formats-enzyme-linked immunosorbent assays in competitive and sandwich configurations, immunoturbidimetric assays delivered as fixed-time or rate-based systems, and lateral flow assays employing colloidal gold, fluorescent, or magnetic labels. These technological distinctions drive variability in throughput, cost, and sensitivity.

End users range from ambulatory surgical centers to diagnostic laboratories, hospitals, and specialty clinics, each setting defined by unique workflow demands and procurement channels. Finally, sample type segmentation covers plasma, serum, synovial fluid, and whole blood, reflecting the diagnostic preferences and logistical constraints encountered in diverse clinical environments. Together, these segmentation insights illuminate the multifaceted pathways through which manufacturers and service providers can optimize market positioning.

Regional Variations Driving Market Trajectories

Regional analysis underscores how geographic trends shape the rheumatoid arthritis diagnostic environment. In the Americas, robust healthcare infrastructure and favorable reimbursement policies drive early adoption of advanced immunoassays and high-resolution imaging modalities, with the United States leading investment in research and development. Canada’s publicly funded system emphasizes cost-effective screening tools, creating opportunities for mid-range assay providers.

Europe, Middle East & Africa presents a mosaic of regulatory frameworks and market maturity. Western Europe embraces digital pathology and cross-border laboratory collaborations, while emerging markets in the Middle East and Africa prioritize affordable point-of-care tests to bridge gaps in specialist access. Harmonization efforts within the European Union continue to influence procurement standards and drive consolidation among regional distributors.

In Asia-Pacific, rapid infrastructure expansion in China, Japan, and India is accompanied by rising rheumatoid arthritis prevalence, fueling demand for both serological and imaging diagnostics. Price sensitivity in developing economies encourages partnerships that lower entry barriers and enhance local manufacturing capabilities. Collectively, these regional variations inform tailored go-to-market strategies that address distinct regulatory, economic, and clinical priorities.

Key Players Shaping Diagnostic Innovation

A cadre of leading life science companies is at the forefront of innovation in rheumatoid arthritis diagnostics. Multinational corporations harness extensive research pipelines to advance next-generation immunoassays and imaging technologies, while mid-tier firms focus on niche platforms that deliver cost-effective, high-throughput performance. Strategic collaborations between reagent developers and instrument manufacturers continue to accelerate product launches, leveraging complementary strengths in assay chemistry and automation.

Additionally, emerging diagnostic specialists are carving out market share through flexible contract models and value-added services such as data analytics and quality control programs. Their agility in customizing solutions for specific clinical settings-from small specialty clinics to large hospital networks-underscores the competitive importance of customer-centric approaches. Across the industry, sustained investment in R&D, coupled with an emphasis on regulatory compliance, is driving a wave of product differentiation that will define the next chapter of market leadership.

Strategic Recommendations for Industry Leaders

To capitalize on the evolving diagnostic landscape, industry leaders should prioritize integrated assay portfolios that span both serological and imaging modalities, thereby offering comprehensive solutions to healthcare providers. Investing in digital health platforms and artificial intelligence-enabled analytics will enhance the value proposition by enabling predictive insights and personalized care pathways. Cultivating strategic partnerships with contract manufacturers and regional distributors can mitigate supply chain disruptions and facilitate faster market entry.

Moreover, proactive engagement with regulatory bodies and payer organizations is essential to shape favorable reimbursement policies and streamline approval processes. Companies should also explore innovative pricing models-such as outcome-based agreements-that align cost with clinical efficacy. Finally, empowering healthcare professionals through targeted training programs on the latest diagnostic protocols will drive adoption rates and reinforce long-term customer relationships.

Robust Methodology Underpinning Our Insights

This analysis is grounded in a robust research methodology that combines comprehensive secondary research with targeted primary data collection. Industry reports, regulatory filings, and peer-reviewed publications provided foundational market context, while in-depth interviews with key opinion leaders and supply chain executives enriched our understanding of emerging trends. Data triangulation ensured consistency across multiple information sources, with quantitative and qualitative findings subjected to rigorous cross-validation.

Our methodological framework incorporated advanced analytical techniques, including competitive benchmarking, SWOT analysis, and Porter’s Five Forces, to evaluate market attractiveness and growth drivers. Geographic and segment-level insights were derived from proprietary databases and corroborated through expert panel reviews. Throughout the research process, stringent quality control measures and peer audits upheld the integrity of our conclusions and reinforced the reliability of the strategic recommendations presented herein.

Concluding Perspectives and Next Steps

In summary, the rheumatoid arthritis diagnostics market is experiencing a period of rapid evolution driven by technological breakthroughs, shifting regulatory landscapes, and changing healthcare delivery models. The integration of advanced immunoassays and AI-enhanced imaging techniques is redefining diagnostic accuracy and efficiency. Simultaneously, geopolitical factors such as tariffs and regional reimbursement policies are reshaping supply chains and market access.

By understanding the nuanced segmentation dynamics, regional variations, and competitive forces at play, stakeholders can make informed decisions to capture growth opportunities and maintain resilience against emerging challenges. The recommendations outlined here provide a strategic blueprint for advancing diagnostic innovation and improving patient outcomes on a global scale.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Test Type
    • Anticcp Tests
      • First Generation Ccp
      • Second Generation Ccp
      • Third Generation Ccp
    • Crp Tests
      • Conventional Crp
      • High-Sensitivity Crp
    • Esr Tests
      • Automatic Esr
      • Manual Esr
    • Imaging Tests
      • Ct
      • Mri
      • Ultrasound
      • X-Ray
    • Rheumatoid Factor Tests
      • Iga Rheumatoid Factor
      • Igg Rheumatoid Factor
      • Igm Rheumatoid Factor
  • Technology
    • Chemiluminescent Immunoassay
      • Direct Clia
      • Indirect Clia
    • Enzyme-Linked Immunosorbent Assay
      • Competitive Elisa
      • Sandwich Elisa
    • Immunoturbidimetric Assay
      • Fixed-Time Immunoturbidimetric
      • Rate Immunoturbidimetric
    • Lateral Flow Assay
      • Colloidal Gold Lfa
      • Fluorescent Lfa
      • Magnetic Lfa
  • End User
    • Ambulatory Surgical Centers
    • Diagnostic Laboratories
    • Hospitals
    • Specialty Clinics
  • Sample Type
    • Plasma
    • Serum
    • Synovial Fluid
    • Whole Blood
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • bioMérieux SA
  • Beckman Coulter, Inc.
  • Ortho Clinical Diagnostics, Inc.
  • DiaSorin S.p.A
  • Bio-Rad Laboratories, Inc.
  • EUROIMMUN AG

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Rheumatoid Arthritis Diagnosis Tests Market, by Test Type
8.1. Introduction
8.2. Anticcp Tests
8.2.1. First Generation Ccp
8.2.2. Second Generation Ccp
8.2.3. Third Generation Ccp
8.3. Crp Tests
8.3.1. Conventional Crp
8.3.2. High-Sensitivity Crp
8.4. Esr Tests
8.4.1. Automatic Esr
8.4.2. Manual Esr
8.5. Imaging Tests
8.5.1. Ct
8.5.2. Mri
8.5.3. Ultrasound
8.5.4. X-Ray
8.6. Rheumatoid Factor Tests
8.6.1. Iga Rheumatoid Factor
8.6.2. Igg Rheumatoid Factor
8.6.3. Igm Rheumatoid Factor
9. Rheumatoid Arthritis Diagnosis Tests Market, by Technology
9.1. Introduction
9.2. Chemiluminescent Immunoassay
9.2.1. Direct Clia
9.2.2. Indirect Clia
9.3. Enzyme-Linked Immunosorbent Assay
9.3.1. Competitive Elisa
9.3.2. Sandwich Elisa
9.4. Immunoturbidimetric Assay
9.4.1. Fixed-Time Immunoturbidimetric
9.4.2. Rate Immunoturbidimetric
9.5. Lateral Flow Assay
9.5.1. Colloidal Gold Lfa
9.5.2. Fluorescent Lfa
9.5.3. Magnetic Lfa
10. Rheumatoid Arthritis Diagnosis Tests Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Diagnostic Laboratories
10.4. Hospitals
10.5. Specialty Clinics
11. Rheumatoid Arthritis Diagnosis Tests Market, by Sample Type
11.1. Introduction
11.2. Plasma
11.3. Serum
11.4. Synovial Fluid
11.5. Whole Blood
12. Americas Rheumatoid Arthritis Diagnosis Tests Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Rheumatoid Arthritis Diagnosis Tests Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Rheumatoid Arthritis Diagnosis Tests Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. F. Hoffmann-La Roche AG
15.3.2. Abbott Laboratories
15.3.3. Siemens Healthineers AG
15.3.4. Thermo Fisher Scientific Inc.
15.3.5. bioMérieux SA
15.3.6. Beckman Coulter, Inc.
15.3.7. Ortho Clinical Diagnostics, Inc.
15.3.8. DiaSorin S.p.A
15.3.9. Bio-Rad Laboratories, Inc.
15.3.10. EUROIMMUN AG
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET MULTI-CURRENCY
FIGURE 2. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET MULTI-LANGUAGE
FIGURE 3. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY FIRST GENERATION CCP, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SECOND GENERATION CCP, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY THIRD GENERATION CCP, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CONVENTIONAL CRP, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY HIGH-SENSITIVITY CRP, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY AUTOMATIC ESR, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MANUAL ESR, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY X-RAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IGA RHEUMATOID FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IGG RHEUMATOID FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IGM RHEUMATOID FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY DIRECT CLIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY INDIRECT CLIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY FIXED-TIME IMMUNOTURBIDIMETRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RATE IMMUNOTURBIDIMETRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COLLOIDAL GOLD LFA, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY FLUORESCENT LFA, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MAGNETIC LFA, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SERUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SYNOVIAL FLUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 87. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 88. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 89. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 90. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 91. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 92. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 93. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 95. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 96. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 97. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 98. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 100. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 101. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 107. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 108. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 109. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 110. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 111. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 166. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 167. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 168. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 169. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 170. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 171. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 172. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 174. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 175. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 176. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 177. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 179. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 180. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 181. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 182. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 183. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 184. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 185. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 187. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 188. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 189. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 190. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 205. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 206. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 207. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 208. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 209. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 210. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 211. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 212. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 213. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 214. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 215. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 216. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 218. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 219. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 220. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 221. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 222. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 223. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 224. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 225. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 226. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 227. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 228. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 229. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 265. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 266. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 270. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 271. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTICCP TESTS, 2018-2030 (USD MILLION)
TABLE 272. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CRP TESTS, 2018-2030 (USD MILLION)
TABLE 273. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ESR TESTS, 2018-2030 (USD MILLION)
TABLE 274. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 275. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR TESTS, 2018-2030 (USD MILLION)
TABLE 276. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 277. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 278. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 279. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, 2018-2030 (USD MILLION)
TABLE 280. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2030 (USD MILLION)
TABLE 28

Companies Mentioned

The companies profiled in this Rheumatoid Arthritis Diagnosis Tests market report include:
  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • bioMérieux SA
  • Beckman Coulter, Inc.
  • Ortho Clinical Diagnostics, Inc.
  • DiaSorin S.p.A
  • Bio-Rad Laboratories, Inc.
  • EUROIMMUN AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.23 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.11 Billion
Compound Annual Growth Rate4.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Rheumatoid Arthritis Diagnosis Tests - Global Strategic Business Report - Product Image

Rheumatoid Arthritis Diagnosis Tests - Global Strategic Business Report

  • Report
  • 441 Pages
  • Global
From
Rheumatoid Arthritis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Rheumatoid Arthritis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 211 Pages
  • Global
From
Rheumatoid Arthritis Diagnostic Tests Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Rheumatoid Arthritis Diagnostic Tests Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 184 Pages
  • Global
From
Collagen Vascular Diseases Market by Disease Indication, Therapy Type, End User, Route Of Administration, Distribution Channel - Global Forecast to 2030 - Product Image

Collagen Vascular Diseases Market by Disease Indication, Therapy Type, End User, Route Of Administration, Distribution Channel - Global Forecast to 2030

  • Report
  • 193 Pages
  • Global
From
United States Autoimmune Disease Diagnostics Market, By Region, Competition, Forecast and Opportunities, 2019-2029F - Product Image

United States Autoimmune Disease Diagnostics Market, By Region, Competition, Forecast and Opportunities, 2019-2029F

  • Report
  • 83 Pages
  • United States
From

About the Market

The Rheumatoid Arthritis Test market within the In Vitro Diagnostics sector is a rapidly growing segment. It is used to diagnose and monitor the progression of the autoimmune disorder, Rheumatoid Arthritis. Tests are used to detect the presence of autoantibodies in the blood, which are associated with the disease. The tests are used to diagnose the disease, as well as to monitor the effectiveness of treatments. The market is driven by the increasing prevalence of Rheumatoid Arthritis, as well as the development of new technologies and tests. The market is also driven by the increasing demand for early diagnosis and treatment of the disease. Some of the major players in the Rheumatoid Arthritis Test market include Abbott Laboratories, Bio-Rad Laboratories, Siemens Healthineers, Roche Diagnostics, and Thermo Fisher Scientific. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.